Posted on September 30, 2009
Filed Under Uncategorized, iPass (IPAS) | 2 Comments
iPass (IPAS) is another low-risk technology stock, that is trading at a depressed valuation, but I believe is on the cusp of renewed growth. Even more importantly, investors are currently being rewarded for their patience in IPAS with management promising continued cash returns via the payout of excess capital to shareholders.
>>Read MorePosted on September 23, 2009
Filed Under Uncategorized, MethylGene (MYG.TO) | Leave a Comment
With the success of my last biotech pick, MYRX, I’ve been scouring the markets looking for other biotech values. MethylGene seems to fit the bill.
>>Read MorePosted on September 17, 2009
Filed Under Uncategorized, CSOL | 1 Comment
It would appear that CSOL has limited downside at current prices, and on the upside, should the company succeed in garnering some attention via new clean energy deals in China, I would expect the stock to rise, especially given the low market cap and the continued hype surrounding China’s solar push.
>>Read More